Västra Hamnen Corp. Finance

Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

Gabather: TOTEMS-study delayed, not derailed

  • Issues with clinical test material delays TOTEMS-study
  • New chairman elected at the AGM
  • We keep our fair value of SEK 0.092 per share

Before releasing its Q2 2025 report, Gabather announced that the TOTEMS-study would be delayed due to issues with the clinical trial material. Meanwhile, changes have taken place in the company’s board, with a new chairman being elected. Despite challenges, we maintain our fair value of SEK 0,092 per share.

The full report is available here.

Datum 2025-09-01, kl 12:00
Källa MFN